Enterprise Value

-881.8M

Cash

951M

Avg Qtr Burn

-138.2M

Short % of Float

0.98%

Insider Ownership

41.29%

Institutional Own.

44.03%

Qtr Updated

06/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

NDA

Submission

Phase 2b

Update

Phase 2

Update

Phase 1

Update

Failed

Discontinued

Rademikibart (CBP-201) (Th2 cell modulator) Details
Chronic rhinosinusitis, Chronic rhinosinusitis with nasal polyps

Failed

Discontinued